Data from the ORBITA-2 randomized, placebo-controlled trial emphasize that patient age alone should not be the deciding ...

In-hospital mortality was significantly lower in patients aged 90 years or older treated with PCI compared with medical management.

New data reveals that percutaneous coronary intervention (PCI) can be safely performed before, during, or after transcatheter aortic valve replacement (TAVR) for patients with stable coronary artery ...

Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB) to a control group consisting of drug-eluting stent (DES) and balloon angioplasty (BA ...

Renee Y. Hsia ([email protected]), University of California San Francisco, San Francisco, California. Yu-Chu Shen, Naval Postgraduate School, Monterey, California; and National Bureau of Economic ...

Washington, D.C. – May 1, 2025 – New findings from FAVOR III China Trial, presented today as late-breaking science at the Society for Cardiovascular Angiography & Interventions (SCAI) 2025 Scientific ...

A statewide effort to get hospitals in Michigan to lower their procedural radiation levels for PCI resulted in a steady decrease over a 6-year period, new data show. “We were really pleased to see ...

Performing percutaneous coronary intervention (PCI) significantly improved outcomes in patients with stable coronary artery disease (CAD) and severe aortic stenosis selected for transcatheter aortic ...

The dual approach, though rare, was linked to fewer 2-year MACE and lower long-term costs compared with angiography alone.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Reflow Medical, Inc. announced that it has received FDA commercial clearance for its coraCatheters™, a complete line of state-of-the-art microcatheters ...

The risk for cardiovascular events is reduced in statin-treated patients with elevated triglycerides and a history of percutaneous coronary intervention (PCI) who receive icosapent ethyl, according to ...